Results :
No patients were lost during follow-up.
Very few side effects were reported: 2 patients (6.7%) experienced a
severe worsening of their pain in the immediate post-operative period.
Both patients were then significantly improved by their first follow-up
visit at 8 weeks.
VAS scores were significantly improved (Table 2) for dysmenorrhoea (80
vs 25: p=0.001), dyspareunia (71 vs 28: p=0.02), and pelvic pain outside
of menstruation (67 vs 28: p=0.03). Quality of life scores all improved
dramatically. The sexual activity questionnaire scores also improved,
with a significantly reduced level of discomfort (4.8 vs. 2.2: p=0.02)
and improvement in habit (0,2 vs 1,9: p=0,03). 9 patients (30%) had
positive criteria for pelvic hypersensitivity. In this group, the
improvement was not significant for all scores.
In this study’s follow-up, 39% of patients were given new injections
before the reappearance of PUS.